Phase II trial of imatinib mesylate in patients with metastatic melanoma

Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We conducted a phase II trial of imatinib in patients with metastatic melanoma expressing at least one of these PTKs. Twenty-one patients whose tumours expressed at least one...

Full description

Saved in:
Bibliographic Details
Main Authors: Kim, K B, Eton, O, Davis, D W, Frazier, M L, McConkey, D J, Diwan, A H, Papadopoulos, N E, Bedikian, A Y, Camacho, L H, Ross, M I, Cormier, J N, Gershenwald, J E, Lee, J E, Mansfield, P F, Billings, L A, Ng, C S, Charnsangavej, C, Bar-Eli, M, Johnson, M M, Murgo, A J, Prieto, V G
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2008
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2528157/
https://ncbi.nlm.nih.gov/pubmed/18728664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604482
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items